The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson and Co. (BD) ...

BD (NYSE: BDX) announced that it reached an agreement with the SEC to resolve an investigation related to its Alaris system.

Becton, Dickinson settles with SEC for $175M over misleading investors on software flaws in Alaris pumps. Read more here.

BD will pay a civil penalty to resolve charges it misled investors about risks associated with sales of its Alaris infusion pump, the Securities and Exchange Commission said.

According to the notice, if a pneumatic valve fails, a pump problem alarm will be raised, which could potentially delay or ...

Becton, Dickinson and Co. (BDX) or BD, a New Jersey-based medical device manufacturer, has agreed to pay $175 million to the U.S.

The SEC has announced a $175 million settlement with Becton Dickinson for misleading investors about risks tied to its Alaris infusion pump. The charges involve the company's failure to disclose ...

The FDA said Fresenius Kabi told customers to remove its Ivenix large-volume infusion pumps from use for repair.

An increasing prevalence of chronic diseases is expected to drive the global infusion pump market to rise by $4.99b through ...

Becton, Dickinson & Co. has agreed to a $175 million fine over Securities and Exchange Commission claims it repeatedly misled investors about one of its most important products.